Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age

Seth Chekata Inzaule, Michael R. Jordan, Amandine Cournil, Marco Vitoria, Giovanni Ravasi, Fatim Cham, Linh Vi Le, Janet Dzangare, Ndapewa Hamunime, Nicholus Mutenda, Avelin Aghokeng, Annez Bissek, Serge Billong, Pontiano Kaleebu, Meg Doherty, Silvia Bertagnolio

Research output: Contribution to journalArticlepeer-review

Abstract

Use of dolutegravir-based first-line antiretroviral therapy (ART) in response to rising levels of pretreatment HIV drug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be limited, given safety concerns for birth defects in women of child-bearing potential. Pooled data from 11 nationally representative surveys show that NNRTI PDR in women is nearly twice that in men, exceeding 10% in 8 of 11 countries monitored, suggesting the urgent need for a non-NNRTI-based ART regimen in this population.

Original languageEnglish (US)
Pages (from-to)1797-1799
Number of pages3
JournalAIDS
Volume33
Issue number11
DOIs
StatePublished - Sep 1 2019

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age'. Together they form a unique fingerprint.

Cite this